Pfizer reveals positive data from Phase 3 trial of ABROCITINIB
Category: #health  By Mateen Dalal  Date: 2019-10-14
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Pfizer reveals positive data from Phase 3 trial of ABROCITINIB

Atopic Dermatitis (AD) is a chronic skin disease characterized by skin barrier defects and inflammation. It results in itching, induration (hardening)/papulation (formulation of papules), and oozing/crusting and affects up to 10% of adults and up to 20% of children in the world. Many researchers and pharmaceutical firms are carrying out clinical trials to develop drugs to treat this disease.

Pfizer Inc. is one such organization which has reportedly announced results of its Phase 3, 12-week, pivotal study in patients who are suffering from atopic dermatitis. Abrocitinib, the firm’s investigational JAK1 inhibitor, has shown positive results and has met all key secondary as well as co-primary endpoints in patients aged 12 years and above.

According to the trial’s safety data, both assessed doses of abrocitinib (100mg and 200mg) were well tolerated and are consistent with companion study (JADE MONO-2) from the JADE (JAK1 Atopic Dermatitis Efficacy and Safety) global development program.

Moreover, the number of subjects who achieved each co-primary and secondary efficacy endpoint was statically higher with abrocitinib as compared to placebo by the end of week 12.

Reports cite that the co-primary endpoints of the trial were an IGA (Investigator Global Assessment) score of clear (0) or almost clear (1) skin and two-point or more improvement compared to baseline, and at least a 75% or greater change in their EASI score from baseline.

Furthermore, key secondary endpoints were a four-point or more decrease in itch severity assessed using the pruritus NRS (Numerical Rating Scale), and the magnitude of decrease in the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD).

Apparently, a considerable number of patients showed a response during the first two to four weeks in the dosing period. Both doses were well-tolerated with patients. Moreover, discontinuation rates were noted to be low as compared to placebo.

Michael Corbo, Chief Development Officer, Inflammation & Immunology of Pfizer Global Product Development, stated that there is a vital need for additional treatment options for patients who are suffering from moderate to severe atopic dermatitis. Corbo added that, if the drug is approved, abrocitinib would be the first oral, once daily treatment option for patients.

SourceCredit–https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_positive_phase_3_data_at_the_28th_congress_of_the_european_academy_of_dermatology_and_venereology_for_abrocitinib_in_moderate_to_severe_atopic_dermatitis

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Chevrolet Camaro could be replaced by a potential all-electric sedan

Chevrolet Camaro could be replaced by a potential all-electric sedan

By Mateen Dalal

Reportedly, General Motors Company is planning to replace the Chevrolet Camaro with an all-electric performance sedan in a few years with the existing model likely to be phased out by 2024. There have many reports about discontinuing the Camaro&rsqu...

Sequoia India launches Spark Fellowship to support female entrepreneurs

Sequoia India launches Spark Fellowship to support female entrepreneurs

By Mateen Dalal

The Spark fellowship program is for women entrepreneurs in India and Southeast Asia. The year-long program is aimed at bringing more gender diversity and supporting startups led by women. Sequoia Capital has recently revealed the launch of a yea...

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

By Mateen Dalal

U.S. President Joe Biden will reportedly nominate Jonathan Kanter, a competition lawyer, and fervid Google critic, to head the antitrust division of the Justice Department. Kanter has been actively representing several companies in competition cases...